耐信上市没？

The Japanese prescription drug (esomeprazole) is a proton pump inhibitor used for the initial and long-term treatment of gastroesophageal reflux disease (GORD), including erosive reflux esophagitis (including erosive esophagitis). It can be used for the long-term maintenance treatment of esophagitis and the prevention of GORD recurrence, as well as the symptomatic treatment of GORD disease. Nexium has the advantages of shorter treatment course, more stable efficacy, faster and longer-lasting effect, and higher HP ulcer eradication rate. It is currently the latest generation of drugs for the treatment of peptic ulcers. Today we will learn more about whether Nexium is listed on the market?

In 2000, the oral formulation of Nexium (esomeprazole) was first launched in Sweden. In 2001, it was approved by the FDA to be launched in the United States under the trade name Nexium. In 2003, Nexium sodium for injection developed by AstraZeneca was first launched in Sweden and was approved for marketing in the United States in 2005.

  On July 30, 2020, AstraZeneca announced that China’s National Medical Products Administration (NMPA) had officially approved Nexium injection for the prevention of stress ulcer bleeding in severe patients.

The mechanism of action of Nexium (esomeprazole) is the same as that of omeprazole, that is, when protonated under acidic conditions, Nexium is converted into a compound sulfenamide that inhibits H+/K+-ATPase activity. It quickly combines with the sulfhydryl group of cysteine on H+/K+-ATPase to form a disulfide bond, thereby inactivating the enzyme, specifically inhibiting H+/K+-ATPase activity in gastric parietal cells and thereby inhibiting gastric acid secretion. Existing research on acid-suppressing ability shows that intravenous administration of Nexium has the same acid-suppressing effect as oral administration of Nexium when administered repeatedly.

In a clinical comparative study between Nexium (esomeprazole) and omeprazole in the treatment of reflux esophagitis, the total effective rate of Nexium was 97.18%, which was significantly higher than that of omeprazole, which was 84.51%. There was no significant difference in the incidence of adverse reactions. Chen Caiming has done a cost-effectiveness analysis of omeprazole and Nexium in the treatment of duodenal ulcer. The recovery rate of the Nexium group was 92.6%, which was higher than omeprazole's 78.6%. The results proved that Nexium has cost and effect advantages.

Patients who use Nexium for a long time should be monitored regularly. When some adverse reactions occur, such as unexplained weight loss, repeated vomiting, difficulty swallowing and other symptoms, they should stop taking the drug in time and go to the hospital to consult a professional doctor to avoid delaying treatment. cause unnecessary negative impacts. 

The above is the content of the launch of (esomeprazole), I hope it can help you!

Recommended related hot articles: /newsDetail/75699.html